Back to search results

Treating Skin Cancers with Laser and Tirbanibulin Ointment

This study is looking at a new way to treat common skin cancers like basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Researchers want to see if using a non-ablative fractional laser (a type of laser that treats skin without removing the top layer) along with tirbanibulin ointment 1% can clear these cancers. You might be able to join if you are 18 or older, have BCC or SCC confirmed by a biopsy, and haven't been treated for it in another way. The study aims to see if this treatment can clear the cancer and prevent it from coming back for at least 5 years. The current status of this study is unclear, and it plans to enroll 100 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 100 participants.
What's involved
You will receive fractional laser treatment. If your cancer is more advanced, you may also need to apply tirbanibulin ointment for 5 nights after the laser procedure.
Compensation
Not stated in the trial record.
Follow-up
Your skin cancer will be monitored for recurrence for 5 years after enrollment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07010692

Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment

Recruiting
PHASE1Ages 18+InterventionalTreatment
Bruce Robinson, MD
~100 participants
Updated 2025-09-17 on ClinicalTrials.gov
What's tested:Tirbanibulin ointment 1%non-ablative fractional laser

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Clearance of skin cancer by evidence of no clinical and/or histological recurrence after 5 years.
Measured over From enrollment to the end of follow-up monitoring at 5 years.

Conditions

Keratinocyte Carcinoma
Basal Cell Carcinomas
Squamous Cell Carcinoma
Skin Cancer

Explore related trials

Basal Cell CarcinomaKeratinocyte CarcinomaSquamous Cell Carcinoma

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Bruce Robinson, MD · PRINCIPAL_INVESTIGATOR · Bruce Robinson, MD

Who to contact

Gillian Nanni, Research Coordinator, BS
[email protected]
212-750-7121
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Cannot be pregnant at the time of treatment

What this trial measures

  • Clearance of skin cancer by evidence of no clinical and/or histological recurrence after 5 years.From enrollment to the end of follow-up monitoring at 5 years.

    Participants will be monitored at 1 month post-procedure then biannually thereafter for 5 years. Site with be observed for clinical recurrence. Optional biopsy at each visit.